Jefferies analyst Anthony Petrone added Haemonetics to his firm’s Franchise Picks list citing the recent pullback in the shares and his view that the company is still well positioned to see “substantial” earnings upside as the NexSys cycle plays out. He believes a stock price of $150-plus is likely over time and keeps a Buy rating on Haemonetics with a $125 price target.
Wednesday, May 1, 2019
Syros Pharmaceuticals plans to report data from Phase 1 trial of SY-1365 in Q4
Syros plans to report initial clinical data in the fourth quarter of 2019 from the expansion portion of its ongoing Phase 1 trial, including initial efficacy and safety assessments from the cohort evaluating SY-1365 as a single agent in high-grade serous ovarian cancer patients who have had three or more prior lines of therapy; initial safety and pharmacokinetic data from the cohort evaluating SY-1365 in combination with carboplatin in high-grade serous ovarian cancer patients who have had one or more prior lines of therapy; and initial safety, efficacy and mechanistic data from the cohort evaluating SY-1365 as a single agent in patients with advanced solid tumors accessible for biopsy. Syros expects to report additional data from these cohorts, including potential proof-of-concept data from the ongoing cohort in high-grade serous ovarian cancer patients who have had one or more prior lines of therapy, in 2020. Syros also expects to report potential proof-of-concept data from an ongoing cohort evaluating SY-1365 as a single agent in patients with relapsed ovarian clear cell cancer and initial data from an ongoing cohort in hormone receptor -positive CDK4/6 inhibitor-resistant breast cancer patients in 2020.
Syros Pharmaceuticals plans to complete studies of SY-5609 in 2019
Syros plans to complete investigational new drug-enabling studies of SY-5609 in 2019 to support the initiation of a Phase 1 oncology trial in early 2020.
Cantor reiterates Overweight on Evolus after ‘solid execution’ in Q1
Cantor Fitzgerald analyst Louise Chen says Evolus posted a quarter of “solid execution.” The analyst continues to think Jeuveau’s value proposition is underappreciated and that it will pick up more market share than anticipated. Ahead of what she expects to be a better than expected launch of Jeuveau, Chen reiterates an Overweight rating on Evolus with a $35 price target. , The U.S. and other launches should drive Evolus shares higher, says the analyst.
GlaxoSmithKline reports Q1 adjusted EPS 30.1%, up 22% AER, up 18% CER
Reports total group sales GBP7.66B. Pharmaceuticals sales GBP 4.2 billion, +4% AER, +2% CER; Vaccines GBP 1.5 billion, +23% AER, +20% CER; Consumer Healthcare GBP 2.0 billion, flat AER, +1% CER. Total Group operating margin 18.6%. Adjusted Group operating margin 28.2%, +1.6 percentage points AER, +1.0 percentage point CER. Emma Walmsley, CEO, GSK said: “We have made a strong start to 2019, which is an important year of execution for GSK, with growth in sales, operating margins and earnings per share in Q1, in line with our expectations. Strengthening our pipeline remains our number one priority and we reported positive data for several potential new medicines in HIV and Oncology during the quarter. I am also pleased to report that integration planning for our new proposed Consumer Healthcare business is going well and, subject to relevant approvals, we continue to expect to complete this transaction in the second half of the year. We look forward to building on the progress made this quarter.”
GlaxoSmithKline backs 2019 adjusted EPS view down 5%-9% CER
The company said: “In 2019, we continue to expect Adjusted EPS to decline in the range of -5% to -9% at CER. This guidance reflects the recent approval of a substitutable generic competitor to Advair in the US and the expected impact of the Tesaro acquisition and assumes that the proposed Consumer Healthcare nutrition disposal closesby the end of 2019 and the proposed Consumer Healthcare Joint Venture with Pfizer closes during H2 2019. GSK expects to maintain the dividend for 2019 at the current level of 80p per share.”
VBI Vaccines reports Q1 EPS (15c), one estimate (22c)
Reports Q1 revenue $360,000, one estimate $200,000. “2019 has the potential to be a transformative year for VBI, marked by clinical milestones across all four of our lead programs, and as such, the first quarter of 2019 was characterized by intense focus on the execution of our ongoing clinical programs,” said Jeff Baxter, President and CEO, VBI Vaccines Inc. “In April 2019, all subjects in the Sci-B-Vac pivotal Phase 3 PROTECT study completed clinical visits, including follow-up visits for safety, which confirms the timeline to top-line data. This data read-out is the most significant clinical milestone in the history of VBI and we remain diligently focused and excited as we advance towards the data read-out, expected mid-year this year, 2019.”
Subscribe to:
Posts (Atom)